



Current Agreements

Dealdoc

Supply and development agreement for cardiovascular generic drug

Medicure
Apicore

Jan 06 2016

Supply and development agreement for cardiovascular generic drug

Companies:	Medicure Apicore
Announcement date:	Jan 06 2016
Deal value, US\$m:	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jan 06 2016
Industry sectors:	Generic pharma Specialty pharma
Exclusivity:	Exclusive
Asset type:	Compound
Therapy areas:	Cardiovascular
Technology types:	Small molecules
Deal components:	Development Supply

Financials

Deal value, US\$m:	n/d
---------------------------	-----

Termsheet

Medicure is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug.

The project is a collaboration between Medicure International, and Apicore US LLC, a leading-edge manufacturer of generic active pharmaceutical ingredients.

The collaborative project is focused on the development of an intravenous abbreviated New Drug Application ("ANDA") drug product for an acute cardiovascular indication.

Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.

Press Release

WINNIPEG, Jan. 6, 2016 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore"), a leading-edge manufacturer of generic active pharmaceutical ingredients ("API's").

The collaborative project is focused on the development of an intravenous abbreviated New Drug Application ("ANDA") drug product for an acute cardiovascular indication. Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights. The companies anticipate filing the ANDA with the U.S. Food and Drug Administration by the end of 2016.

Medicure, through its affiliates, is a minority shareholder in Apicore and holds an option to acquire all of the issued shares of Apicore until July 2017, as previously announced on July 3, 2014.

About Apicore

Apicore is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. Apicore offers a wide portfolio of services ranging from manufacture of API's for the generic industry to custom synthesis for early phase pharmaceutical research, and branded products. For more information, please visit Apicore online at www.apicore.com.

About Medicure Inc.

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.

Filing Data

Not available.

Contract

Not available.